Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Par Drugs and ChemicalsNSE:PAR -1.02%77 EV-to-EBIT is 4.63 as of Aug. 27, 2026, which is 63% below its 10-year median of 12.43. GuruFocus rates NSE:PAR with a GF Score™ of 77/100 and a GF Value™ of ₹208.63 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 691 Drug Manufacturers companies, Par Drugs and Chemicals ranks better than 89.87% on this metric.
Par Drugs and Chemicals (NSE:PAR) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Par Drugs and Chemicals's Enterprise Value for the quarter that ended in Mar. 2026 was ₹554 Mil.
Par Drugs and Chemicals's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹174 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Par Drugs and Chemicals EV-to-EBIT Related Terms
Par Drugs and Chemicals EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Par Drugs and Chemicals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Par Drugs and Chemicals EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Par Drugs and Chemicals's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Par Drugs and Chemicals's EV-to-EBIT falls into.
Par Drugs and Chemicals's current Enterprise Value is ₹806 Mil.
Par Drugs and Chemicals's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹174 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Par Drugs and Chemicals (NSE:PAR) has a EV-to-EBIT of 4.63 as of Aug. 27, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Par Drugs and Chemicals and its competitors. This is 63% below median its historical median of 12.43. Over the past decade, Par Drugs and Chemicals' EV-to-EBIT has ranged from 3.45 to 23.00. According to the industry distribution chart, Par Drugs and Chemicals ranks #70 out of 691 companies in the Drug Manufacturers industry, placing it in the top 10.1%.
Is Par Drugs and Chemicals' EV-to-EBIT too high?
Par Drugs and Chemicals' current EV-to-EBIT of 4.63 is 63% below median its 10-year median of 12.43. Over the past 10 years, this metric has ranged from a low of 3.45 to a high of 23.00. The Drug Manufacturers industry median EV-to-EBIT is 15.77. Par Drugs and Chemicals' value of 4.63 is 70.6% below this industry median. Based on the distribution chart, Par Drugs and Chemicals ranks #70 out of 691 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Par Drugs and Chemicals has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Par Drugs and Chemicals' EV-to-EBIT compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Par Drugs and Chemicals ranks #70 out of 691 companies for EV-to-EBIT. This places Par Drugs and Chemicals in the top 10% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 15.77. Par Drugs and Chemicals' value of 4.63 is 70.6% below this benchmark. Historically, Par Drugs and Chemicals' own EV-to-EBIT has ranged from 3.45 to 23.00 over the past decade. While the company's 10-year median is 12.43 vs. the industry median of 15.77, Par Drugs and Chemicals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.77, based on 691 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Par Drugs and Chemicals's current EV-to-EBIT of 4.63 is 70.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Par Drugs and Chemicals and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Par Drugs and Chemicals's current EV-to-EBIT is 4.63, which is 63% below median its own 10-year median of 12.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Par Drugs and Chemicals stock overvalued right now?
Based on GuruFocus' analysis, Par Drugs and Chemicals (NSE:PAR) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹208.63, compared to a current price of ₹99.54 — trading 52.3% below its estimated fair value. The current EV-to-EBIT is 4.63, which is 63% below median its 10-year median of 12.43 and 70.6% below the Drug Manufacturers industry median of 15.77. Par Drugs and Chemicals' overall GF Score™ is 77/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Par Drugs and Chemicals (NSE:PAR), the current EV-to-EBIT is 4.63 as of Aug. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Par Drugs and Chemicals (NSE:PAR) Overvalued in 2026?
Based on GuruFocus' analysis, Par Drugs and Chemicals stock appears to be undervalued.
The current stock price of ₹99.54 is trading 52.3% below its estimated GF Value™ of ₹208.63.
GuruFocus considers Par Drugs and Chemicals to be Significantly Undervalued.
Key valuation signals for NSE:PAR:
EV-to-EBIT: 4.63 (63% below median its 10-year median of 12.43)
GF Value™: ₹208.63 vs. price of ₹99.54 (52.3% below fair value)
Industry Position: 70.6% below the Drug Manufacturers median (#70 of 691)
No single metric tells the full story. See the NSE:PAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Par Drugs and Chemicals Ltd manufactures active Pharmaceutical Ingredients (APIs) and fine chemicals, serving domestic and international markets. Specializing in essential magnesium-based compounds and other specialty chemicals such as Magnesium Hydroxide, Magnesium Trisilicate, Magnesium Carbonate, various grades of Magnesium Oxide, Dried Aluminum Hydroxide Gel, and Sucralfate USP, the Company produces high-quality bulk drugs used in the formulation of finished pharmaceutical products like tablets, capsules, and liquids. Committed to maintaining stringent quality standards and utilizing manufacturing processes, the Company plays a vital role in supplying reliable ingredients that ensure the safety, efficacy, and stability of pharmaceutical formulations internationally.
77GF Score
Get the complete analysis for NSE:PAR
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:PAR has been successfully added to your 
